EOS imaging to Present at the 29th Annual Piper Jaffray Healthcare Conference

EOS imaging to Present at the 29th Annual Piper Jaffray Healthcare Conference

Share this story with your network

November 20, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – SME), the pioneer of 2D/3D orthopedic medical imaging, today announced that Marie Meynadier, Chief Executive Officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY.

Event: 29th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 29, 2017
Time: 10:30 am ET / 4:30 pm CET

Investors attending the conference who would like to schedule a one-on-one meeting with EOS imaging management may do so by contacting their Piper Jaffray representative, or Emma Poalillo of The Ruth Group at epoalillo@theruthgroup.com.

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging service dedicated to osteo-articular pathologies and orthopaedics, as well as the associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan, China and the European Union (EC). It posted revenues of €30.8 million in 2016 and employed 132 people at December 2016, including an R&D team of 43 engineers. The group is based in Paris and has five subsidiaries: in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

EOS imaging has been selected to integrate the EnterNext © PEA – SME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
CFO
Pierre Schwich, +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent, +33 (0)1 44 71 94 96
eosimaging@newcap.eu
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*